Obinutuzumab is a humanized monoclonal antibody that inhibits CD20 for cancer therapy. In combination with chlorambucil, it was approved as a first-line treatment for chronic lymphocytic leukemia. It also can be used to treat follicular lymphoma.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.